Our top pick for
Pulse Biosciences, Inc is a medical instruments & supplies business based in the US. Pulse Biosciences shares (PLSE) are listed on the NASDAQ and all prices are listed in US Dollars. Pulse Biosciences employs 82 staff and has a market cap (total outstanding shares value) of USD$839.5 million.
|52-week range||USD$5.11 - USD$45.82|
|50-day moving average||USD$32.4979|
|200-day moving average||USD$18.616|
|Wall St. target price||USD$46|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-2.166|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Gross profit TTM||USD$0|
|Return on assets TTM||-75.06%|
|Return on equity TTM||-185.9%|
|Market capitalisation||USD$839.5 million|
TTM: trailing 12 months
There are currently 1.3 million Pulse Biosciences shares held short by investors – that's known as Pulse Biosciences's "short interest". This figure is 22.1% down from 1.6 million last month.
There are a few different ways that this level of interest in shorting Pulse Biosciences shares can be evaluated.
Pulse Biosciences's "short interest ratio" (SIR) is the quantity of Pulse Biosciences shares currently shorted divided by the average quantity of Pulse Biosciences shares traded daily (recently around 163928.70249017). Pulse Biosciences's SIR currently stands at 7.63. In other words for every 100,000 Pulse Biosciences shares traded daily on the market, roughly 7630 shares are currently held short.
However Pulse Biosciences's short interest can also be evaluated against the total number of Pulse Biosciences shares, or, against the total number of tradable Pulse Biosciences shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Pulse Biosciences's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 Pulse Biosciences shares in existence, roughly 50 shares are currently held short) or 0.0795% of the tradable shares (for every 100,000 tradable Pulse Biosciences shares, roughly 80 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Pulse Biosciences.
Find out more about how you can short Pulse Biosciences stock.
We're not expecting Pulse Biosciences to pay a dividend over the next 12 months.
Over the last 12 months, Pulse Biosciences's shares have ranged in value from as little as $5.11 up to $45.82. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Pulse Biosciences's is 1.798. This would suggest that Pulse Biosciences's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It engages in the research and development, and commercialization of CellFX system that provides a precise and non-thermal cellular treatment technology delivering nanosecond duration energy pulses that impact cells in treated tissue while sparing surrounding non-cellular tissue primarily for dermatology applications. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was founded in 2014 and is headquartered in Hayward, California.
Everything we know about the Toast Inc IPO, plus information on how to buy in.
Everything we know about the Cyxtera IPO, plus information on how to buy in.
Everything we know about the ATI Physical Therapy IPO, plus information on how to buy in.
Everything we know about the Sportradar IPO, plus information on how to buy in.
Everything we know about the Longboard Pharmaceuticals Inc IPO, plus information on how to buy in.
Everything we know about the Prometheus Biosciences Inc IPO, plus information on how to buy in.
Everything we know about the Olo Inc IPO, plus information on how to buy in.
Everything we know about the China Eco-Materials Group Co Limited IPO, plus information on how to buy in.
Everything we know about the Gain Therapeutics Inc IPO, plus information on how to buy in.
Everything we know about the Karat Packaging Inc IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.